Tags

Type your tag names separated by a space and hit enter

Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis.
Curr Med Res Opin. 2006 Jun; 22(6):1181-91.CM

Abstract

BACKGROUND

There is an increasing body of evidence to support the benefits of reducing low-density lipoprotein cholesterol (LDL-C) levels and this has been reflected in a lowering of LDL-C goals recommended by international guidelines. Therefore, there is a growing need for effective lipid-modifying therapies to optimise the achievement of these more stringent LDL-C goals.

OBJECTIVE

A meta-analysis of data pooled from five studies participating in the DISCOVERY (DIrect Statin COmparison of LDL-C Values: an Evaluation of Rosuvastatin therapY) Programme was performed to compare the effect of rosuvastatin treatment with other statins in real-life clinical practice.

RESULTS

These studies included 6743 patients with hypercholesterolaemia from different ethnicities, countries and cultural environments. The meta-analysis showed that significantly more patients receiving rosuvastatin 10 mg achieved the 2003 European LDL-C goals compared with those who received atorvastatin 10 mg or simvastatin 20 mg (p < 0.001 for both comparisons). A significantly greater proportion of patients receiving rosuvastatin 10 mg also achieved the 2003 European total cholesterol goal compared with those on atorvastatin 10 mg (p < 0.001).

CONCLUSIONS

The meta-analysis showed that rosuvastatin was more effective than comparator statins at lowering LDL-C levels and enabling patients to achieve lipid goals at recommended start doses. In addition, all statins studied were well tolerated and confirmed that rosuvastatin had a similar safety profile to other statins.

Authors+Show Affiliations

Fowey Surgery, Fowey, Cornwall, UK. alan.middleton@foweydocs.demon.co.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16846551

Citation

Middleton, A, et al. "Achieving 2003 European Lipid Goals With Rosuvastatin and Comparator Statins in 6743 Patients in Real-life Clinical Practice: DISCOVERY Meta-analysis." Current Medical Research and Opinion, vol. 22, no. 6, 2006, pp. 1181-91.
Middleton A, Binbrek AS, Fonseca FA, et al. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr Med Res Opin. 2006;22(6):1181-91.
Middleton, A., Binbrek, A. S., Fonseca, F. A., Wilpshaar, W., Watkins, C., & Strandberg, T. E. (2006). Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Current Medical Research and Opinion, 22(6), 1181-91.
Middleton A, et al. Achieving 2003 European Lipid Goals With Rosuvastatin and Comparator Statins in 6743 Patients in Real-life Clinical Practice: DISCOVERY Meta-analysis. Curr Med Res Opin. 2006;22(6):1181-91. PubMed PMID: 16846551.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. AU - Middleton,A, AU - Binbrek,A S, AU - Fonseca,F A H, AU - Wilpshaar,W, AU - Watkins,C, AU - Strandberg,T E, PY - 2006/7/19/pubmed PY - 2006/11/3/medline PY - 2006/7/19/entrez SP - 1181 EP - 91 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 22 IS - 6 N2 - BACKGROUND: There is an increasing body of evidence to support the benefits of reducing low-density lipoprotein cholesterol (LDL-C) levels and this has been reflected in a lowering of LDL-C goals recommended by international guidelines. Therefore, there is a growing need for effective lipid-modifying therapies to optimise the achievement of these more stringent LDL-C goals. OBJECTIVE: A meta-analysis of data pooled from five studies participating in the DISCOVERY (DIrect Statin COmparison of LDL-C Values: an Evaluation of Rosuvastatin therapY) Programme was performed to compare the effect of rosuvastatin treatment with other statins in real-life clinical practice. RESULTS: These studies included 6743 patients with hypercholesterolaemia from different ethnicities, countries and cultural environments. The meta-analysis showed that significantly more patients receiving rosuvastatin 10 mg achieved the 2003 European LDL-C goals compared with those who received atorvastatin 10 mg or simvastatin 20 mg (p < 0.001 for both comparisons). A significantly greater proportion of patients receiving rosuvastatin 10 mg also achieved the 2003 European total cholesterol goal compared with those on atorvastatin 10 mg (p < 0.001). CONCLUSIONS: The meta-analysis showed that rosuvastatin was more effective than comparator statins at lowering LDL-C levels and enabling patients to achieve lipid goals at recommended start doses. In addition, all statins studied were well tolerated and confirmed that rosuvastatin had a similar safety profile to other statins. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/16846551/Achieving_2003_European_lipid_goals_with_rosuvastatin_and_comparator_statins_in_6743_patients_in_real_life_clinical_practice:_DISCOVERY_meta_analysis_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079906X100177 DB - PRIME DP - Unbound Medicine ER -